Literature DB >> 23737456

Prevalence and incidence of hypoparathyroidism in the United States using a large claims database.

Julia Powers1, Karen Joy, Aimee Ruscio, Hjalmar Lagast.   

Abstract

Hypoparathyroidism is a rare endocrine disorder whose incidence and prevalence have not been well defined. This study aimed to 1) estimate the number of insured adult patients with hypoparathyroidism in the United States and 2) obtain physician assessment of disease severity and chronicity. Prevalence was estimated through calculation of diagnoses of hypoparathyroidism in a large proprietary health plan claims database over a 12-month period from October 2007 through September 2008 and projected to the US insured population. Incidence was also calculated from the same database by determining the proportion of total neck surgeries resulting in either transient (≤6 months) or chronic (>6 months) hypoparathyroidism. A physician primary market research study was conducted to assess disease severity and determine the percentage of new nonsurgical patients with hypoparathyroidism. Incidence data were entered into an epidemiologic model to derive an estimate of prevalence. The diagnosis-based prevalence approach estimated 58,793 insured patients with chronic hypoparathyroidism in the United States. The surgical-based incidence approach yielded 117,342 relevant surgeries resulting in 8901 cases over 12 months. Overall, 7.6% of surgeries resulted in hypoparathyroidism (75% transient, 25% chronic). The prevalence of chronic hypoparathyroidism among insured patients included in the surgical database was estimated to be 58,625. The physician survey found that 75% of cases treated over the past 12 months were reported due to surgery and, among all thyroidectomies and parathyroidectomies and neck dissections performed in a year, 26% resulted in transient hypoparathyroidism and 5% progressed to a chronic state. In conclusion, the two claims-based methods yielded similar estimates of the number of insured patients with chronic hypoparathyroidism in the United States (~58,700). The physician survey was consistent with those calculations and confirmed the burden imposed by hypoparathyroidism.
© 2013 American Society for Bone and Mineral Research.

Entities:  

Keywords:  DISORDERS OF CALCIUM/PHOSPHATE METABOLISM; EPIDEMIOLOGY; HYPOPARATHYROIDISM; PARATHYROID HORMONE AND PARATHYROID GLAND

Mesh:

Year:  2013        PMID: 23737456     DOI: 10.1002/jbmr.2004

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  38 in total

Review 1.  Recombinant Human Parathyroid Hormone (1-84): A Review in Hypoparathyroidism.

Authors:  Esther S Kim; Gillian M Keating
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

2.  Parathyroid hormone therapy for hypoparathyroidism.

Authors:  Natalie E Cusano; Mishaela R Rubin; John P Bilezikian
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2014-09-10       Impact factor: 4.690

Review 3.  Impact of recombinant PTH on management of hypoparathyroidism: a systematic review.

Authors:  Y Ramakrishnan; H C Cocks
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-01-08       Impact factor: 2.503

4.  Calcium, vitamin D or recombinant parathyroid hormone for managing post-thyroidectomy hypoparathyroidism.

Authors:  Ovie Edafe; Claudia E Mech; Sabapathy P Balasubramanian
Journal:  Cochrane Database Syst Rev       Date:  2019-05-22

Review 5.  Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review.

Authors:  Matthias Büttner; Thomas J Musholt; Susanne Singer
Journal:  Endocrine       Date:  2017-08-18       Impact factor: 3.633

6.  The PGRIS and parathyroid splinting concepts for the analysis and prognosis of protracted hypoparathyroidism.

Authors:  Antonio Sitges-Serra
Journal:  Gland Surg       Date:  2017-12

Review 7.  Incidence, prevalence and risk factors for post-surgical hypocalcaemia and hypoparathyroidism.

Authors:  Ovie Edafe; Sabapathy Prakash Balasubramanian
Journal:  Gland Surg       Date:  2017-12

8.  PTH(1-84) replacement therapy for the treatment of hypoparathyroidism.

Authors:  Natalie E Cusano; Mishaela R Rubin; John P Bilezikian
Journal:  Expert Rev Endocrinol Metab       Date:  2015-01-01

Review 9.  Bone imaging in hypoparathyroidism.

Authors:  B C Silva; M R Rubin; N E Cusano; J P Bilezikian
Journal:  Osteoporos Int       Date:  2016-08-30       Impact factor: 4.507

Review 10.  The association between hypoparathyroidism and cognitive impairment: a systematic review.

Authors:  A Sardella; F Bellone; N Morabito; S Minisola; G Basile; F Corica; A Catalano
Journal:  J Endocrinol Invest       Date:  2020-09-14       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.